drugset / Trial / NCT01357447

Pulmozyme for Sjogren's Associated Cough

NCT01357447

Phase 1 Withdrawn UConn Health
RandomizedCrossoverDouble-blindSupportive care

Summary

Patients with Sjogren's disease have destruction of the mucus secreting cells in the airway. This manifestation of the disease leads to the common complaint of persistent dry cough that is seen in many of these patients. This study is aimed at determining whether the regular use of Pulmozyme will result in decreased cough and improved quality of life.

Timeline

Start
2011-05
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator dornase alfa Protein / enzyme biologic 2.5 mg Inhaled

Indications